Go Epic Health Initiates New Clinical Studies for Cholesterade® Belleair Bluffs, FL — September 29, 2016 – Go Epic Health, Inc., announces commencement of new clinical studies for their flagship product Cholesterade®. James Price, CEO of Go Epic Health stated, “We are pleased to announce that we have initiated new clinical studies for Cholesterade® to update the initial studies that were performed by the product creator, the late Dr. J. Robert Cade. In addition, we will be conducting new studies side by side with the original formula to validate the efficacy of a new natural patent pending technology we have introduced. Cade, himself conducted a detailed clinical study at the time of its creation and had fantastic results pertaining to reducing total cholesterol and triglyceride levels while at the same time increasing HDLC/LDLC ratios. While it has been several years since those initial studies were completed, we felt the need to conduct new studies. The new clinical studies are being conducted at Bucks County Clinical Research in Pennsylvania under the direct supervision of Dr. Richard Goldfarb. These studies will be ongoing and we will publish the results at different durations of the studies.” About Go Epic Health Go Epic Health is a nutritional product holding company which owns the intellectual property and worldwide manufacturing and distribution rights to Cholesterade®, a natural cholesterol reducing product created by the late Dr. Robert Cade, creator of Gatorade ®. Go Epic’s wholly owned subsidiary, American Retail Alliance, markets and distributes Cholesterade® as well as other new and innovative consumer goods through the nation’s largest retail pharmacy chain stores, drug and health food stores, multilevel organizations, and product specific catalogs. Wholly owned subsidiary Eagle Labs is a product and contract manufacturing company specializing in manufacturing food, cosmetics,
dietary supplements, liquid bottling and product formulation. For further information, please visit www.goepichealth.com. ForwardLooking Statements Disclosure: This press release may contain “forwardlooking statements” within the meaning of the federal securities laws. In this context, forwardlooking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” beliefs,” estimates,” expects,” intends,” plans,” seeks,” will” and other terms with similar meaning. These forwardlooking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forwardlooking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forwardlooking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions. Contact: Woody Junot, President